Citigroup Inc Adaptimmune Therapeutics PLC Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.73 - $1.04 $57 - $82	79 Added 0.01%	582,275 $454,000
Q2 2023 Aug 10, 2023	BUY	$0.9 - $1.51 $522,486 - $876,616	580,541 Added 35078.01%	582,196 $535,000
Q1 2023 May 11, 2023	SELL	$1.06 - $2.16 $325 - $663	-307 Reduced 15.65%	1,655 $1,000
Q4 2022 Feb 09, 2023	SELL	$1.05 - $2.53 $4,921 - $11,858	-4,687 Reduced 70.49%	1,962 $2,000
Q3 2022 Nov 10, 2022	SELL	$1.06 - $2.41 $26,268 - $59,724	-24,782 Reduced 78.85%	6,649 $7,000
Q2 2022 Aug 10, 2022	BUY	$1.33 - $2.28 $13,159 - $22,558	9,894 Added 45.94%	31,431 $53,000
Q1 2022 May 12, 2022	SELL	$1.73 - $4.06 $14,725 - $34,558	-8,512 Reduced 28.33%	21,537 $44,000
Q4 2021 Feb 10, 2022	SELL	$3.5 - $5.68 $41,797 - $67,830	-11,942 Reduced 28.44%	30,049 $113,000
Q3 2021 Nov 10, 2021	BUY	$3.44 - $6.37 $144,449 - $267,482	41,991 New	41,991 $217,000

145M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $96.4M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.